País: Francia
Idioma: inglés
Fuente: HMA (Heads of Medicines Agencies)
imidacloprid chlorohydrate 75 mg
Vetoquinol S.A.
QC09AA16
Powder for oral solution
Imidapril
Dogs
2008-04-04
11834 Prilium 75 mg/-FINAL SPC /Renewal 1/14 PRILIUM 75 MG POWDER FOR ORAL SOLUTION Powder for oral solution SUMMARY OF PRODUCT CHARACTERISTICS 11834 Prilium 75 mg/-FINAL SPC /Renewal 2/14 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT PRILIUM 75 mg powder for oral solution for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION POWDER/VIAL Imidapril hydrochloride 75 mg Sodium benzoate (E 211) 30 mg Excipient to 0.805 g SOLUTION AFTER RECONSTITUTION Imidapril hydrochloride 2.5 mg Sodium benzoate(E 211) 1.0 mg Excipient to 1 ml For full list of excipients, see 6.1. 3. PHARMACEUTICAL FORM Powder for oral solution. Vial containing a white powder. After reconstitution, the solution is limpid and colourless. 4. CLINICAL PARTICULARS 4.1. Target species Dogs weighing over 2 kg 4.2. Indications for use, specifying the target species In dogs: treatment of moderate to severe heart failure caused by mitral regurgitation or by dilated cardiomyopathy. 4.3. Contraindications Do not use in dogs with low blood pressure. Do not use in dogs with acute renal insufficiency. Do not use in dogs with congenital heart disease Do not use in dogs hypersensitive to an ACE inhibitor Do not use in dogs with hemodynamically relevant stenoses (aortic stenosis, mitral valve stenosis, pulmonal stenosis) Do not use in dogs with obstructive hypertrophic cardiomyopathy 4.4. Special warnings for each target species None 4.5. Special precautions for use i) Special precautions for use in animals The use of ACE inhibitors in dogs with hypovolaemia/dehydration can lead to acute hypotension. In su Leer el documento completo